Pathways to Precision: Pioneering Biomarkers in CIDP
This Medical symposium explores how chronic inflammatory demyelinating polyneuropathy (CIDP) is evolving closer towards personalized medicine and individualized patient care. This 1-hour program examines cutting-edge biomarkers—including NfL, inflammatory markers, and digital biomarkers—that can identify underlying drivers of residual disability early in the disease course, with the ultimate goal of optimizing patient management to improve patient outcomes.
Note from the speakers
Symposium Highlights
Library of Congress
This Symposium is intended for medical and scientific exchange purposes with health care professionals and patient advocacy group leadership only. This program is non-promotional, is sponsored by Sanofi Medical, and the content contained in this presentation was developed by Sanofi Medical in collaboration with the speakers. The speakers were compensated by Sanofi in connection with this presentation. This presentation is not eligible for CME. This Symposium discusses treatment agents that are investigational and no conclusions regarding safety and efficacy should be drawn. For approved agents referenced in this Symposium, please refer to the prescribing information available in your country.